AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

Sanjeev Kumar Panchal has stepped down as Managing Director of AstraZeneca Group. The company has appointed Praveen Rao ...

Drugmaker AstraZeneca revealed on Friday that it has entered a strategic research collaboration with Chinese firm CSPC Pharmaceuticals Group.

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

AstraZeneca PLC ADR closed 14.46% short of its 52-week high of $87.68, which the company reached on August 30th.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Understand every aspect of the global economy – and know how to make your next move.

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

AstraZeneca PLC closed 17.61% short of its 52-week high of £133.88, which the company reached on September 3rd.